Sucampo Co-Founder and Chairman Emeritus, Dr. Ryuji Ueno, to Receive Visionary Award From the Foundation Fighting Blindness
March 25 2014 - 6:45AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that the Foundation
Fighting Blindness (Foundation), a national nonprofit driving
sight-saving research, will honor Sucampo's Co-Founder and Chairman
Emeritus, Ryuji Ueno, M.D., Ph.D., Ph.D., with the Foundation's
Visionary Award, in recognition of Dr. Ueno's longstanding
commitment to helping patients with eye diseases. The 12th Annual
D.C. "For the Love of Sight" Visionary Awards Dinner will take
place on Tuesday, April 1, at 6 p.m. Eastern, at the Ritz-Carlton -
Downtown, Washington, D.C., to benefit research into preventions,
treatments and cures for vision-robbing retinal diseases including
macular degeneration, retinitis pigmentosa (RP), Usher syndrome and
related conditions that affect more than 10 million Americans.
Dr. Ueno discovered unoprostone isopropyl, an ophthalmic agent
currently approved for primary open angle glaucoma and ocular
hypertension in the United States and Japan. Based on this
discovery, Sucampo's development partner, R-Tech Ueno, Ltd., is
currently in a Phase 3 study in Japan of a different formulation of
the ophthalmic agent for RP.
"We are pleased that the Foundation's Visionary Award recognizes
Dr. Ueno's accomplishments and dedication to those suffering from
generative forms of eye disease," said Peter Greenleaf, Sucampo's
Chief Executive Officer. "By building on Dr. Ueno's leadership and
advancements in the ophthalmic area, we will continue to strive in
making quality medicines to help meet the unmet medical needs of
patients around the world."
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical
company, is focused on the discovery, development and
commercialization of drugs based on ion channel activators knows as
prostones. Discovered by the company's scientific co-founder, Dr.
Ueno, prostones are naturally occurring fatty acid metabolites with
unique physiological activities. Sucampo has two marketed products
– AMITIZA® and RESCULA® – and a pipeline of prostone-based product
candidates in clinical development. A global company, Sucampo is
headquartered in Bethesda, Maryland, and has operations in Japan,
the United Kingdom and Switzerland. For more information, please
visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are
registered trademarks of Sucampo AG. AMITIZA is a registered
trademark of Sucampo AG. RESCULA is a registered trademark of
R-Tech Ueno, Ltd, and has been licensed to Sucampo AG.
Sucampo Forward-Looking Statement
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements are based on management's current
expectations and involve risks and uncertainties, which may cause
results to differ materially from those set forth in the
statements. The forward-looking statements may include statements
regarding product development, product potential, future financial
and operating results, and other statements that are not historical
facts. The following factors, among others, could cause actual
results to differ from those set forth in the forward-looking
statements: the impact of pharmaceutical industry regulation and
health care legislation; Sucampo's ability to accurately predict
future market conditions; dependence on the effectiveness of
Sucampo's patents and other protections for innovative products;
the risk of new and changing regulation and health policies in the
U.S. and internationally and the exposure to litigation and/or
regulatory actions. No forward-looking statement can be guaranteed
and actual results may differ materially from those projected.
Sucampo undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this
presentation should be evaluated together with the many
uncertainties that affect Sucampo's business, particularly those
mentioned in the risk factors and cautionary statements in
Sucampo's most recent Form 8-K and 10-K, which Sucampo incorporates
by reference.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn
(Sucampo Pharmaceuticals). Twitter LinkedIn
CONTACT: Silvia Taylor
Senior Vice President, Investor Relations and
Corporate Communications
Sucampo Pharmaceuticals, Inc.
1-240-223-3718
staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2024 to May 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From May 2023 to May 2024